Lixte Biotechnology(LIXT.US)

Last Updated 19:00:00 ET
longbridge loading

LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update | LIXT Stock News

StockTitan·
US
LIXT
+5.54%
US
ARKG
+3.35%
US
PBE
+0.35%
StockTitan·
US
LIXT
+5.54%
US
ARKG
+3.35%
US
PBE
+0.35%

Lytix Biopharma Grants Share Options to Board Member Under Incentive Plan

Tip Ranks·
US
IBBQ
+0.82%
US
XBI
+0.81%
US
IXJ
+0.67%
Tip Ranks·
US
IBBQ
+0.82%
US
XBI
+0.81%
US
IXJ
+0.67%

Lixte Biotechnology | 10-K: FY2025 Revenue: USD 0

Earnings Watch·
US
LIXT
+5.54%
Earnings Watch·
US
LIXT
+5.54%

Lixte Biotechnology Holdings 10-K: $0 Revenue, $(1.26) EPS

TradingView·
US
XLV
+0.69%
US
IXJ
+0.67%
US
FBT
+0.69%
TradingView·
US
XLV
+0.69%
US
IXJ
+0.67%
US
FBT
+0.69%

LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year | LIXT Stock News

StockTitan·
US
VHT
+0.64%
US
FBT
+0.69%
US
ARKG
+3.35%
StockTitan·
US
VHT
+0.64%
US
FBT
+0.69%
US
ARKG
+3.35%

Lytix Biopharma Calls April AGM and Proposes No 2025 Dividend

Tip Ranks·
US
LIXT
+5.54%
US
LSBCF
+35.14%
US
AMAM
0.00%
Tip Ranks·
US
LIXT
+5.54%
US
LSBCF
+35.14%
US
AMAM
0.00%

Lytix Biopharma Marks Pivotal 2025 With Strong Melanoma Data and Capital Raise

Tip Ranks·
US
IXJ
+0.67%
US
VHT
+0.64%
US
BBH
+0.64%
Tip Ranks·
US
IXJ
+0.67%
US
VHT
+0.64%
US
BBH
+0.64%
© 2026 Longbridge｜Disclaimer